Tower Research Capital LLC (Trc) Cardiff Oncology, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,697 shares of CRDF stock, worth $19,962. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,697
Previous 32,718
85.64%
Holding current value
$19,962
Previous $72,000
83.33%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CRDF
# of Institutions
90Shares Held
12.3MCall Options Held
813KPut Options Held
91.1K-
Black Rock Inc. New York, NY2.63MShares$11.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$9.23 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$3.94 Million0.0% of portfolio
-
State Street Corp Boston, MA833KShares$3.54 Million0.0% of portfolio
-
Mai Capital Management663KShares$2.82 Million0.02% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $184M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...